Candel Therapeutics Inc. (CADL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Candel Therapeutics highlights third quarter milestones across cancer immunotherapy pipeline
Candel Therapeutics Inc (NASDAQ:CADL) reported encouraging clinical progress across its cancer immunotherapy pipeline, along with the release of its third quarter 2025 financial results. The company recently presented new Phase 3 subgroup analyses of CAN-2409 in localized prostate cancer showing statistically significant improvement in disease-free survival and updated survival data from its Phase 1b CAN-3110 trial in recurrent high-grade glioma, underscoring the potential of its multimodal immunotherapies.
Candel Therapeutics secures $130M to fund lead program – ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr. Paul Peter Tak talked with Proactive about the company's recently secured $130 million term loan facility with Trinity Capital.
Candel Therapeutics strengthens Research Advisory Board with appointment of immunology expert
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Dr Bali Pulendran, a leading authority in systems immunology and vaccinology, to its Research Advisory Board. Dr Pulendran is the Violetta L.
Candel Therapeutics secures $130M loan to advance cancer therapy trials
Candel Therapeutics Inc (NASDAQ:CADL) said it has inked a five-year, $130 million term loan facility with Trinity Capital to strengthen its balance sheet and support late-stage development and potential commercialization of its cancer immunotherapies. The facility includes four tranches, with $50 million drawn at closing.
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now
Candel Therapeutics has generated favorable phase 3 data supportive of a BLA submission in prostate cancer, but it won't come until the end of next year. In the meantime, the market appears to be anticipating very little forward momentum in other pipeline candidates. CADL presents a high-risk/high-reward situation at this depressed market cap.
Candel trial shows promise for gene therapy in prostate cancer
Candel Therapeutics Inc (NASDAQ:CADL) said Monday that its experimental treatment CAN-2409 significantly extended the time patients lived without their prostate cancer returning, according to results from a large late-stage study presented at the annual meeting of the American Society for Radiation Oncology. The therapy, also known as aglatimagene besadenovec, was tested in 745 men with intermediate-to-high-risk localized prostate cancer, a group typically treated with radiation therapy but still facing a roughly 30% chance of recurrence within 10 years.
Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors
Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is financially solid after a $92 million capital raise, ensuring a cash runway through 2027 and supporting late-stage clinical and regulatory milestones. Candel's differentiated oncolytic viral platform and FDA Fast Track designations position it as a leader in a rapidly maturing immuno-oncology niche.
Candel Therapeutics secures RMAT for prostate cancer – ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs. CEP Dr Paul Peter Tak said Candel has had “another very successful quarter”, highlighting that its lead program CAN-2409 achieved its primary endpoint in early localized, newly diagnosed prostate cancer.
Candel Therapeutics advances toward prostate cancer therapy filing after trial success
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA granted it Regenerative Medicine Advanced Therapy (RMAT) status. The clinical-stage biotech reported a narrower second-quarter loss, backed by stronger trial results and financing that will help support launch readiness activities.
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409
Candel Therapeutics Inc (NASDAQ:CADL) announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational immunotherapy CAN-2409 for the treatment of pancreatic cancer. The designation adds to CAN-2409's existing Orphan Drug Designation and Fast Track Designation from the US Food and Drug Administration for pancreatic ductal adenocarcinoma.
Candel Therapeutics expands Russell Index presence following 2025 reconstitution
Candel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective with the opening of the US markets on June 30.
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
